ClinicalTrials.gg
TerminatedNCT03367195Updated Jan 7, 2021

Efficacy and Safety of DLBS2411 in the Management of GERD

A Phase 3 interventional study of Omeprazole and DLBS2411 in Gastroesophageal Reflux Disease (GERD), sponsored by Dexa Medica Group. Terminated at 5 sites in Indonesia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment

Why this study was terminated
Very low recruitment rate. The Study Site classifies as tertiary referral hospital. Therefore, GERD Patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a 2-arm, prospective, double-blind double-dummy, randomized-controlled study comparing DLBS2411 at a dose of 250 mg twice daily with omeprazole at a dose of 20 mg twice daily, given before morning and evening meals, for an 8-week course of therapy. Subjects should avoid taking meals 2-3 hours before bedtime.

The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation.

Recent study of DLBS2411 which was conducted in healthy volunteers, demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit patients with gastric acid disorders such as in gastroesophageal reflux disease (GERD).

Read the detailed description

There will be 2 groups of treatment; each group will consist of 129 subjects with the treatment regimens for 8 weeks:

Treatment I : 1 capsule of Omeprazole 20 mg and 1 placebo caplet of DLBS2411, twice daily Treatment II : 1 caplet of DLBS2411 250 mg and 1 placebo capsule of omeprazole, twice daily

Each study medication will be administered twice daily, 30 minutes before morning (the first) and evening (the last) meals.

The eligible subjects will be randomly allocated to receive study medication (Treatment 1 or Treatment 2) for 8 weeks of treatment, in a double blind fashion. They will be asked to come to the clinic every 4-week interval throughout the study period. Treatment Group 1 will receive Omeprazole twice daily and Placebo DLBS2411 twice daily. While Treatment Group 2 will receive DLBS2411 twice daily and Placebo Omeprazole twice daily.

Subjects will be evaluated for treatment efficacy at baseline and at interval of 4 weeks over the 8-week course of therapy. Throughout the 8-week therapy, subjects should record the frequency (presence and absence) of each of GERD symptoms (heartburn, regurgitation, epigastric pain, nausea) daily in the provided Patient's Diary. The severity of each symptom experienced should also be self-evaluated and recorded.

The safety profile of study medication other than vital signs and adverse event will be measured at baseline and end of study.

Along the study, subjects should avoid taking meals 2-3 hours before bedtime. All subjects will be under direct supervision of a medical doctor during the study period.

02

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • GERD
  • DLBS2411
  • omeprazole
03

In context

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

This study's enrollment of 32 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agree to participate in the study under signed .
  2. Male or female subjects aged 18-65 years old.
  3. Subjects with diagnosis of GERD confirmed by endoscopy, with esophagitis grade A-B according to the LA Classification.
  4. Able to take oral medication.
  5. Subjects or subjects' legally acceptable representatives are able and willing to record adverse events in diary.
  6. Subjects or subjects' legally acceptable representatives have the ability to comply with the trial protocol, including instruction for taking trial medication.

Exclusion criteria

Exclusion Criteria:

  1. For females of : pregnancy and breast-feeding.

    • Patients must accept pregnancy tests during the trial if menstrual cycle is missed
    • Fertile patients must use a reliable and effective
  2. Subjects with Zollinger Ellison syndrome or peptic ulcer diseases.
  3. History or current evidence of Barrett's esophagus, esophageal strictures, odynophagia, pyloric stenosis, esophageal motility disorders (such as achalasia, scleroderma), anatomic esophageal abnormality (such as large hiatal hernia), pill-induced esophagitis.
  4. Helicobacter pylori positive as confirmed by urea breath test (UBT).
  5. History of esophageal, gastric or intestinal surgery including vagotomy.
  6. Presence of comorbid diseases, such as symptomatic coronary artery disease (CAD) or cardiovascular disease, pulmonary disease (including asthma), hemostasis disorder, pancreatitis, malabsorption, or inflammatory bowel disease, and any other chronic diseases (including chronic cough, laryngitis), any serious infection(s), or (ies).
  7. Inadequate liver function defined as or alkaline phosphatase > 2.5 times .
  8. Inadequate renal function defined as estimated (eGFR) \< 60 mL/min.
  9. Taking any proton pump inhibitors (PPIs) or sucralfate within 14 days prior to screening.
  10. Requiring regular and chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), systemic , aspirin, anticholinergics, cholinergics, spasmolytics, or opiates, misoprostol or prokinetics.
  11. to proton pump inhibitors.
  12. Subjects with chronic alcoholism (>40 g alcohol/day) or drug abuse.
  13. Active heavy smokers (i.e. consuming >10 cigarettes per day).
  14. Participation in any other clinical studies within 30 days prior to screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Treatment 1

    1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily

    Drug: Omeprazole · Drug: Placebo caplet of DLBS2411

  • Experimental
    Treatment II

    1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily

    Drug: DLBS2411 · Drug: Placebo capsule of Omeprazole

Interventions

  • 1 Omeprazole 20 mg capsules twice daily

  • 1 DLBS2411 caplet 250 mg, twice daily

    Also known as: Redacid

  • DrugPlacebo capsule of Omeprazole

    1 placebo capsule of omeprazole, twice daily

  • DrugPlacebo caplet of DLBS2411

    1 placebo caplet of DLBS2411, twice daily

    Also known as: Placebo caplet of Redacid

06

What researchers measure

Primary outcomes

  1. Healing rate by endoscopy

    Healing rate is defined as proportion of subjects with either complete or achieving lower endoscopic grade of esophagitis (according to the Los Angeles (LA) classification) at Week 8 (end of study).

    Time frame: 8 weeks

Secondary outcomes

  1. Changes in GERD Questionnaire (GERDQ) sum scores

    Changes in GERDQ sum scores from baseline to Week 4 and Week 8 of treatment.

    Time frame: 4 and 8 weeks

  2. Composite heartburn and regurgitation response rate

    Composite heartburn and regurgitation response rate: defined as proportion of subjects with neither heartburn nor acid regurgitation during the last 7 days (complete resolution of heartburn and acid regurgitation) by Week 4 and Week 8.

    Time frame: 4 and 8 weeks

  3. Heartburn response rate

    Heartburn response rate: defined as proportion of subjects with no heartburn during the last 7 days (complete resolution of heartburn) by Week 4 and Week 8 (end of study).

    Time frame: 4 and 8 weeks

  4. Regurgitation response rate

    Regurgitation response rate: defined as proportion of subjects with no regurgitation during the last 7 days (complete resolution of regurgitation) by Week 4 and Week 8 (end of study).

    Time frame: 4 and 8 weeks

  5. Overall response rate

    Overall response rate: defined as proportion of subjects with controlled GERD symptoms by Week 4 and 8 of treatment, defined as proportion categorized as: * complete relief (no GERD symptoms during the last 7-day); * partial relief (a decrease in frequency but not complete relief of GERD symptoms during the last 7-day); and * no response (increase or no change in frequency of GERD symptoms).

    Time frame: 4 and 8 weeks

  6. Vital sign

    Vital sign (blood pressure) from baseline to every follow-up visit including end of study

    Time frame: 4 and 8 weeks

  7. Electrocardiography (ECG)

    Electrocardiography (ECG) at baseline and at the end of study

    Time frame: 8 weeks

  8. Liver function

    Liver function (serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin)from baseline to every follow-up visit including end of study

    Time frame: 4 and 8 weeks

  9. Renal function

    Renal function (serum creatinine and blood urea nitrogen (BUN) level) from baseline to every follow-up visit including end of study

    Time frame: 4 and 8 weeks

  10. Adverse event

    Adverse event, will be observed throughout the study conduct

    Time frame: 4 and 8 weeks

07

Study locations

5 sites
  • Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital
    Bandung, Indonesia
  • Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital
    Jakarta, 10430, Indonesia
  • Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital
    Semarang, Indonesia
  • Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Airlangga Dr. Soetomo Hospital
    Surabaya, Indonesia
  • Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Gadjah Mada Dr. Sardjito Hospital
    Yogyakarta, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in May 2020, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 8, 2017
StartActual
Aug 16, 2018
Primary completionActual
May 4, 2020
CompletionActual
Sep 9, 2020
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03367195
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Aug 16, 2018
Primary completion
May 4, 2020
Completion
Sep 9, 2020
Last update
Jan 7, 2021

Study contacts

Dadang Makmun, SpPD, KGEH
principal investigator · Division of Gastroenterology Department of Internal Medicine Faculty of Medicine, University of Indonesia Dr. Cipto Mangunkusumo National General Hospital, Jakarta Indonesia
Iswan A. Nusi, Prof. KGEH, FINASIM, FACG
principal investigator · Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Airlangga Dr. Soetomo Hospital, Surabaya, Indonesia
Putut Bayupurnama, SpPD, KGEH
principal investigator · Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Gadjah Mada Dr. Sardjito Hospital, Yogyakarta, Indonesia
Hery D. Purnomo, SpPD, KGEH
principal investigator · Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Diponegoro Dr. Kariadi Hospital, Semarang, Indonesia
Dolvy Girawan, M. Kes., SpPD, KGEH
principal investigator · Division of Gastroenterohepatology Department of Internal Medicine Faculty of Medicine, University of Padjajaran Dr. Hasan Sadikin Hospital, Bandung, Indonesia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DLBS2411

Start the discussion